Vivo Bio Tech's Q4 FY 2025-26 Quarterly Results

Result Summary

• Vivo Bio Tech Ltd reported a 4.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 14.4%.
• Its expenses for the quarter were up by 10.8% QoQ and 19.4% YoY.
• The net profit decreased 512.8% QoQ and decreased 586.8% YoY.
• The earnings per share (EPS) of Vivo Bio Tech Ltd declined at 2.52 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Vivo Bio Tech Ltd is a company that operates in the biotechnology sector, focusing on the development and manufacturing of biological products and services. The company is involved in the research and development of pharmaceutical products, particularly in the field of biotechnology, which includes the production of biopharmaceuticals, biologics, and other biotechnology-based products. As of the latest developments, there is no specific information available on any major events or strategic shifts for Vivo Bio Tech Ltd. The company continues to focus on its core operations within the biotechnology industry, providing innovative solutions and products to meet the demands of the healthcare sector.

Revenue

In the fourth quarter of the fiscal year 2026, Vivo Bio Tech Ltd reported a total income of ₹14.23 crores. This represents a quarter-over-quarter (QoQ) increase of 4.2% from the previous quarter's income of ₹13.65 crores. Additionally, on a year-over-year (YoY) basis, the total income increased by 14.4% compared to the ₹12.44 crores reported in the fourth quarter of the fiscal year 2025. These figures suggest a trend of revenue growth over both the quarterly and annual periods, indicating an upward trajectory in the company's income generation during this timeframe.

Profitability

The profitability metrics for Vivo Bio Tech Ltd in Q4FY26 show a significant decline in profit figures. The company reported a profit before tax of ₹0.25 crores, which is an 84.1% decrease from the ₹1.57 crores reported in Q3FY26. Compared to the same quarter last year, there is a 79.8% decline from the ₹1.24 crores in Q4FY25. The tax expense for the quarter was ₹5.41 crores, a substantial increase compared to ₹0.32 crores in the previous quarter and ₹0.18 crores in the same quarter last year. This led to a profit after tax of negative ₹5.16 crores, a stark contrast to the positive profit of ₹1.25 crores in Q3FY26 and ₹1.06 crores in Q4FY25. Earnings per share also reflect this downturn, with a reported value of negative ₹2.52, down from ₹0.56 in the previous quarter and ₹0.69 in the same quarter last year.

Operating Metrics

During the fourth quarter of the fiscal year 2026, Vivo Bio Tech Ltd experienced an increase in total expenses, which amounted to ₹13.38 crores. This represents a 10.8% QoQ increase from ₹12.08 crores in Q3FY26 and a 19.4% YoY increase from ₹11.21 crores in Q4FY25. The expense growth outpaced revenue growth during the quarter, which is a notable aspect of the company's operational performance. These operating metrics highlight a period of increased costs, which have significantly impacted the overall profitability of the company for the quarter.